Evaluation of efficacy of various immunochromatographic rapid tests for dengue diagnosis

Arshi Naz1, Danish Zahid2, Samina Naz Murky3, Muhammad Nadeem4, Bijon Kumar Sil5, Tahir Sultan Shamsi6

ABSTRACT

Objective: The immunochromatographic rapid tests facilitate the early diagnosis of dengue by providing evidence of the presence of virus specific proteins (antigens/antibody) in human blood. Many products for rapid dengue diagnosis are available in the market; the performance of few selected products was evaluated and compared with enzyme linked immuno sorbent assays (ELISA).

Methods: Sera from a large number of patients (n=184) admitted to National Institute of Blood Diseases & Bone Marrow Transplantation (NIBD) were used to determine the efficiency of non-structural (NS) 1, IgA, IgG and IgM based rapid test devices for dengue diagnosis.

Results: The dengue NS1 antigen based device was least efficient while among the antibody based devices the dengue IgA rapid test (RDT) was comparatively better (specificity: 80.95%; sensitivity: 85.21%). This device could detect both primary and secondary dengue infection and was found to be the most sensitive device at all point of sample collection.

Conclusion: The dengue IgA RDT could be a cost effective and efficient rapid test device for timely dengue diagnosis at all levels of healthcare settings.

KEY WORDS: Immunochromatographic rapid test, Enzyme Linked Immuno Sorbent Assay (ELISAs), anti-dengue IgA.

doi: http://dx.doi.org/10.12669/pjms.301.4173

How to cite this:
Naz A, Zahid D, Murky SN, Nadeem M, Sil BK, Shamsi TS. Evaluation of efficacy of various immunochromatographic rapid tests for dengue diagnosis. Pak J Med Sci 2014;30(1):166-171. doi: http://dx.doi.org/10.12669/pjms.301.4173

INTRODUCTION

In the past few decades dengue has become a global health problem infecting millions of individuals annually.1-3 Since its first report in 1994 from the metropolitan city of Karachi dengue virus infection has become one of the expected causes of morbidity and mortality in Pakistan.4,5 All four serotypes of dengue virus (DENV-1 to DENV-4) are currently circulating and now become endemic in Pakistan with highest incidences reported during post monsoon period each year.6 A major outbreak of dengue virus infection in Pakistan was recorded during 2006.7 Clinically apparent disease due to dengue virus varies in severity from mild undifferentiated fever through to more severe forms such as dengue fever (DF) and dengue hemorrhagic fever (DHF). DHF is a vasculopathy characterized by capillary leakage and haematological deregulation; may result in fatal outcomes.8 An early and accurate
Rapid tests for dengue diagnosis

Rapid tests for dengue diagnosis are commercially available diagnostic tools that detect and identify anti-dengue antibodies in the human serum. These tests are often a one-step chromatographic assay which uses murine monoclonal antibodies to capture dengue virus NS1 antigen in human serum or plasma and detected by NS1 antigen polyclonal conjugate. The test is performed with the standard procedure as described in the instruction of the manufacturers. The sensitivity of most of these tests is documented in the supporting literature, and the specificity is high.

**Methods**

**Study design:** A panel of 184 dengue disease suspected human serum samples was used for the evaluation of efficacy of dengue immunochromatographic tests (RDT). The study was conducted during the period of August to December 2010 at National Institute of Blood Diseases (NIBD). A signed informed consent form and detailed questionnaire were obtained from patients involved in this study following institutional review board (IRB) policies. Age range of the study population was 2-65 years.

A probable dengue case may be a patient with presentation of defined clinical symptoms and history of acute febrile illness of 2-7 days with or without haemorrhage. In the present study any sample positive for either dengue specific-antigen (NS1) or antibodies (IgM or IgG or IgA) by RDT screening was considered as positive dengue case. All samples were characterized using dengue acute diagnostics: NS1 Ag Rapid Test (Panbio, Australia), ASSURE<sup>®</sup> dengue IgA Rapid Test (MP Diagnostics, USA) and dengue Duo Cassette (Panbio, Australia).

The efficiencies of all these devices were evaluated by comparing with dengue IgM capture ELISA (Dia. Pro, Italy) and dengue IgG capture ELISA (Dia. Pro, Italy). Complete blood count (CBC) was performed; after proper mixing by automated hematology analyzer; Sysmex XE-2100 (Sysmex Kobe, Japan); to evaluate the clinical parameters of dengue diagnosis (Platelets count, PCV, TLC etc).

**Dengue Antibodies ELISAs:** Dengue IgM-Cap ELISA and IgG-Cap ELISA were used to detect dengue antibodies as per manufacturer’s instruction. Briefly, 100 µl/well of patient sera (diluted 1:100) and controls were added to the assay plate coated with either anti-human IgM or anti-human IgG to capture the IgM or IgG. Both plates were incubated for one hour at 37°C. Then the plates were washed and 100 µl/well of enzyme conjugate was transferred to the assay plates except the blank wells. After 10 minutes, the reaction was stopped by addition of 100 µl/well 1 M phosphoric acid. The OD values were determined at 450 nm. A sample was defined as positive when ratio of sample absorbance and calculated cut-off value was ≥ 1.

**Dengue NS1 Ag Rapid Test:** Dengue NS1 Ag Rapid Test is a one-step chromatographic assay which uses murine monoclonal antibodies to capture dengue virus NS1 antigen in human serum or plasma and detected by NS1 antigen polyclonal antibodies conjugated with gold colloid. Assays were conducted and results were interpreted according to the instruction of manufacturers.

**Dengue IgA Rapid Test:** ASSURE<sup>®</sup>Dengue IgA Rapid Test (WO 2009/139725) is a reverse flow technique.
immunochromatographic rapid test for the qualitative detection of anti-dengue IgA from patient’s biological samples (serum, whole blood or plasma). In this platform, test sample migrates upwards from the sample well and eventually form antibody-antigen complexes with dengue virus antigens in the test window. The bound antibody-antigen complexes is subsequently detected by goat anti-human IgA gold conjugate carried by chase buffer that flows downwards giving a pink-purplish color line in the test window. Control line which contains protein L captures human IgA from patient’s sample and binds with the anti-human IgA-gold conjugate, resulting in pink-purplish color line in the control window. The appearance of control line indicates the proper addition and migration of serum sample and chase buffer. The test was performed as per manufacturer’s instruction for use (IFU) and results were interpreted according to the intensity scale provided with the kit box without knowledge of the results of other tests.

**Dengue Duo IgM/IgG Cassette:** Dengue Duo Cassette is a lateral flow based immunochromatographic rapid test for the qualitative detection of anti-dengue IgM and IgG from patient’s biological samples (serum, whole blood or plasma). The device is designed to detect IgM antibodies to dengue, as well as elevated IgG titers that are indicative of a secondary infection. The rapid tests were read and interpreted according to the manufacturers’ instructions. The positivity of individual marker were calculated separately (IgM or IgG) as well as in combination (IgM and IgG).

**Statistical analysis:** The quantitative variables were expressed as mean, standard deviation, confidence interval and minimum and maximum range. The qualitative variables were mentioned as percentages. The sensitivity and specificity of immunochromatographic tests were analyzed by 2x2 table using MedCalc statistical software, version-11.5 (Broehstraat 52, B-9030 Mariakerke, Belgium). Kappa value was used to test the efficiency and reliability of the rapid devices.

**RESULTS**

**Characteristics of the study population:** The characteristics of the study population (n = 184 cases) that contributed acute sera to the test panel is shown in Table-I. The median duration of illness prior to the test plasma sample being collected was 5 days (range: 2-17). There were 42 patients with no viral antigen (NS1) or serological evidence of acute or recent dengue infection in collected serum specimens. Of 142 dengue positive samples, 97 samples were considered as secondary infection (positive for either IgM and Ig G or positive for IgG by the standard capture ELISAs) and 45 samples were dengue primary infection (positive with IgM capture ELISA and negative with IgG capture ELISA).

**Sensitivity and specificity of dengue immunochromatographic tests versus reference dengue tests:** The sensitivities and specificities of three RDTs against the reference tests i.e. dengue IgM-cap ELISA and IgG-cap ELISA are presented in Table-II. The dengue NS1 antigen based RDT showed 64.08% (91/142) sensitivity compared to 72.54% (103/142) by Den IgM/IgG RT. The individual dengue diagnostic marker of Panbio IgM/IgG RDT showed 63.38% (IgM) and 48.59% (IgG) respectively. The dengue IgA RDT showed higher level of performance over NS1 and IgM/IgG RDT and was found to 85.21% (121/142). In terms of specificity dengue NS1 showed 100% accuracy compared to 69.05% (29/42) and 80.95% (34/45) by dengue IgM/IgG RDT and dengue IgA RDT respectively.

**Immunochromatographic tests sensitivity in primary or secondary infection:** The detection

| Variables | Confirmed dengue cases | Non-dengue febrile illness |
|-----------|------------------------|---------------------------|
| Male      | 52.17% (n=96)          | 15.76% (n=29)             |
| Female    | 25.00% (n=46)          | 7.00% (n=13)              |
| Age       | 28.06±14 (2-65 yrs)    | 27.42±15.2 (6-65 yrs)     |
| Platelets | 80.76±84.8 (2-421 x 109/L) | 70.13±60.22 (11-254 x 109/L) |
| PCV       | 38.97±6.69 (19-52%)    | 39±5.89 (28-47%)          |
| TLC       | 5.32±3.09 (1.09-16.05 x 109/L) | 4.38±2 (0.66-9.37 x 109/L) |
| Day of illness | 5±2.1 (1-14 days) | 5.6±3.4 (3-20 days) |
| Temperatures | 101.97±0.87 (100-105°F) | 101.96±0.75 (101-104°F) |
| Primary infection | 68.31% (n=97) | - |
| Secondary infection | 31.69% (n=45) | - |
of both dengue primary and secondary infected patients by dengue IgA RT was significantly higher than Panbio IgM/IgG Duo RDT and is presented in Table-III. The primary dengue infection was confirmed by positive anti-dengue IgM and negative anti-dengue IgG-cap by reference ELISAs. The dengue IgA RDT detected 91.11% (41/45) dengue primary infected cases compared to 75.56% (34/45) by Dengue IgM/IgG Duo RDT. Like-wise dengue IgA RDT detected 82.47% cases of dengue secondary infection compared to dengue Duo IgM/IgG RDT (71.13%). Moreover, the dengue secondary marker of IgM/IgG RDT (IgG) showed lowest level of detection of dengue secondary infection (51.55%).

**Sensitivity of Immunochromatographic tests by day of illness:** The sensitivity of three RDTs was also evaluated based on the duration of onset of dengue fever, categorized into 6 groups (Table-IV). The dengue IgA RDT showed significantly higher level of detection of dengue cases at all points of collection of samples (day 1-13) compared to dengue Duo IgM/IgG RDT and dengue NS1 RDT.

### Table-II: Efficiency of rapid test devices.

| Rapid Tests         | Sensitivity (95% CI)* | Specificity (95% CI) | Positive Predictive Value (95% CI) | Negative Predictive Value (95% CI) |
|---------------------|-----------------------|----------------------|------------------------------------|-----------------------------------|
| Dengue-IgA RDT      | 85.21% (121/142)      | 80.95% (34/42)       | 93.80%                             | 61.82%                             |
|                     | (78.29% to 90.61%)    | (65.88% to 91.40%)   | (88.15% to 97.28%)                | (47.73% to 74.59%)                |
| Dengue-IgM RDT      | 63.38% (90/142)       | 76.19% (32/42)       | 90.00%                             | 38.10%                             |
|                     | (54.89% to 71.30%)    | (60.55% to 87.95%)   | (82.38% to 95.10%)                | (27.71% to 49.34%)                |
| Dengue-IgG RDT      | 48.59% (69/142)       | 76.19% (32/42)       | 87.34%                             | 30.48%                             |
|                     | (40.13% to 57.12%)    | (60.55% to 87.95%)   | (77.95% to 93.76%)                | (21.87% to 40.22%)                |
| Dengue-IgM/IgG RDT  | 72.54% (103/142)      | 69.05% (29/42)       | 88.79%                             | 42.65%                             |
|                     | (64.42% to 79.68%)    | (52.91% to 82.38%)   | (81.60% to 93.90%)                | (30.72% to 55.23%)                |
| Dengue-NS1 RDT      | 64.08% (91/142)       | 100% (42/42)         | 100%                               | 45.16%                             |
|                     | (55.61% to 71.96%)    | (91.59% to 100.00%)  | (96.03% to 100.00%)               | (34.81% to 55.83%)                |

**DISCUSSION**

Serological assays from a single serum specimen using RDT device, in many instances, provide presumptive diagnosis of dengue infections. The commonly occurring infection in Pakistan is generally dengue fever but rare cases of DHF particularly DSS mostly result in mortality due to improper diagnosis or false negative results on most of the RDT devices. There remains a need for more efficient sero-diagnostic device. Therefore, in this study, we have included acute dengue suspected samples in the comparative evaluation of routine dengue- NS1, IgM, IgG and a new IgA RDT with WHO recommended IgM and IgG capture ELISAs.

The serum IgA levels are documented as another approach for early detection of dengue infection. IgA is the second most abundant antibody in human body. It is found in serum in both primary and secondary dengue infections. During primary infection it appears ~1 day after IgM; requires class switching by somatic hypermutation. Talarmin et al suggested anti-dengue IgA as a marker of
recent dengue infection in dengue endemic areas. In acute secondary infection unlike IgG and IgM antibodies the anti-dengue IgA antibodies appear earlier in serum i.e. even prior to active viremia. Generally, dengue secondary infection is most likely to be associated with the more serious form of the disease, thus the detection of dengue secondary cases at the early stage of infection is of prime importance for proper medical attention to avoid fatal outcomes. The dengue IgA RDT used during this study was found to detect more cases of dengue secondary infection compared to IgG RDT Duo cassette Table-III. These observations are in line with a previous study on dengue IgA RDT. The specificity and sensitivity of dengue IgA RDT in earlier studies were quite similar to our findings 86.70% (85.21%) and 86.05% (80.95%) respectively. Additionally, the level of detection of infection at all stages of disease by IgA RDT was far better (negative predictive value: 61.82%; Table-II). Ahmed & coworkers validated the same IgA RT to be 99.4% sensitive and 99.2% specific with 100% detection of primary dengue cases of all serotypes compared with reverse transcriptase polymerase chain reaction.

Furthermore, among the three tested RDT devices the NS-1 antigen based device was found least efficient with 35.91% (51/142) false negative results. Dengue NS-1 antigen can be found in patient’s serum until the production of anti-NS-1 IgG or in some instances a few days after defervescence. The variable levels of NS-1 antigen in different phases of infection might be due to the immune-complex formation of NS1 antigen with anti-dengue IgG resulting in less sensitive dengue detection in acute-phase secondary infection as reported previously.

**CONCLUSION**

We conclude that the serological testing for early diagnosis of dengue infections could be accomplished by using IgA based RDT at all health care settings during any stage of infection cycle. Moreover, it partially overcomes the limitations associated with ELISAs like handling of single sample without delay.

**ACKNOWLEDGEMENTS**

The authors would like to acknowledge Dr. Nadir, Dr. Khalid Hassan, Rizwan Rehman, Medical Product Technologies, Sure Bio-diagnostics & Pharmaceuticals and Chohan & Company for their help and assistance in this study.

**Conflict of Interest:** Authors have no conflict of interest.

**REFERENCES**

1. Kyle JL and Harris E. Global spread and persistence of dengue. Annu Rev Microbiol. 2008;62:71-92. doi: 10.1146/annurev.micro.62.081307.163005.

2. Gubler DG. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res. 2002;33:30-42.

3. WHO. Dengue and dengue hemorrhagic fever. Fact Sheet No. 117 revised 2009. Geneva, World Z Health Organization, 2009. Available from: www.who.int./mediacentre/factsheets/fs117/en/

4. Chan YC, Salahuddin, NI, Khan J, Tan HC, Seah CL. Dengue haemorrhagic fever outbreak in Karachi, Pakistan, 1994. Trans R Soc Trop Med Hyg. 1995;89:619-620. doi: 10.1016/0035-9203(95)90412-3.

5. Wasay M, Channa R, Jumani M, Zafar A. Changing patterns and outcome of dengue infection; report from a tertiary care hospital in Pakistan. J Pak Med Assoc. 2008;58:488-489.

6. Jahan, F. Dengue fever (DF) in Pakistan. Asia Pacific Family Medicine 2011;10(1):1 doi:10.1186/1471-2296-10-1. [cited 2012 January 22] Available from: http://www.apfmj.com/content/10/1/1

7. Khan E, Kisat M, Khan N, Nasir A, Ayub S, Hassan R. Demographic and clinical features of dengue fever in Pakistan from 2003–2007: A retrospective cross-sectional study. PLoS One. 2010;5(9):e12505. Published online 2010 September 13. doi: 10.1371/journal.pone.0012505 Available from: http://www.plosone.org/article/info

8. TDR/ WHO. 2009. Dengue: Guidelines for diagnosis, treatment, prevention and control. WHO Press, Geneva, Switzerland. Available from whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf
9. Tricou V, Vu HTT, Quynh NVN, Nguyen CVV, Tran HT, Farrar J, et al. Comparison of two dengue NS1 rapid tests for sensitivity, specificity and relationship to viraemia and antibody responses. BMC Infect. Dis. 2010;10:142-149.
10. Blacksell SD, Mammen MP Jr, Thongpaseuth S, Gibbons RV, Jarman RG, Jenjaroen K, et al. Evaluation of the Fanbio dengue virus nonstructural 1 antigen detection and immunoglobulin M antibody enzyme-linked immunosorbent assays for the diagnosis of acute dengue infections in Laos. Diagn Microbiol Infect Dis. 2008;60:43-49. doi:10.1016/j.diagmicrobio.2007.07.011
11. Datta S, Wattal C. Dengue NS1 antigen detection: A useful tool in early diagnosis of dengue virus infection. Indian J Med Microbiol. 2010;28:107-110. doi: 10.4103/0255-0857.62484
12. Tan YY, Sekaran SD, Wang SM, Ahmed F, Hossain A, Sil BK. Development of ASSURE® Dengue IgA Rapid Test for the detection of anti-dengue IgA from dengue infected patients. J Glob Infect Dis. 2011;3(3):233-240. doi: 10.4103/0974-777X.83528.
13. Balmaseda A, Guzman MG, Hammond S, Robleto G, Flores C, Tellez Y, et al. Diagnosis of dengue virus infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum and saliva. Clin Diagnostic Lab Immunol. 2003;10(2):317-322. doi: 10.1128/CDLI.10.2.317-322.2003
14. Hakim ST, Tayyab SM, Qasmi SU and Nadeem SG. An experience with dengue in Pakistan: An expanding problem. Ibnosina J Med B S. 2011;3-8.
15. Nawa M, Takasaki T, Ito M, Inoue S, Morita K, Kurane I. Immunoglobulin A antibody responses in dengue patients: a useful marker for serodiagnosis of dengue virus infection. Clin Diagnostic Lab Immunol. 2005;12(10):1235-1237. doi: 10.1128/CDLI.12.10.1235-1237.2005
16. Guzman MG, Kouri G. Dengue diagnosis; advances and challenges. Int J Infect Dis. 2004;8:69-90. doi:10.1016/j.ijid.2003.03.003
17. Groen J, Velzing J, Copra C, Balentien E, Deubel V, Vorndam V, et al. Diagnostic value of dengue virus-specific IgA and IgM serum antibody detection. Microbes Infect. 1999;1:1085–1090.
18. Talarmin A,Laboeu B, Lenville J and Sarthou JL. Immunoglobin A specific Capture Enzyme-Linked Immunosorbent Assay for diagnosis of dengue fever. J Clin Microbiol. 1998;36(5):1189-1192.
19. Guzman MG, Kouri G, Valdés L, Bravo J, Vázquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Pública. 2002;11:223-227.
20. Ahmed F, Mursalin H, Alam MT, Amin R, Sekaran SD, Wang SM, et al. Evaluation of ASSURE® Dengue IgA Rapid Test using dengue-positive and dengue-negative samples. Diagn Microbiol Infect Dis. 2010;68(4):339-344. doi:10.1016/j.diagmicrobio.2010.07.007
21. Koraka P, Burghoorn-Mass CP, Falconar A, Setiati TE, Djamiatun K, Groen J, et al. Detection of immune-complex-dissociated nonstructural-1 antigen in patients with acute dengue virus infections. J Clin Microbiol. 2003;41(9):4154-4159. doi:10.1128/JCM.41.9.4154-4159.2003

Note: The following posters were also presented from this project:
Comparison of 3 commercial rapid immunochromatographic devices for the diagnosis of acute Dengue virus in Karachi, Pakistan (8th Annual Conference of Infectious Diseases in Islamabad, Pakistan, March 2011)
Diagnosis of Dengue (53rd annual National Student Research Forum in Texas, USA, April 2012)

Author Contribution:
Dr. Arshi Naz: Designed the study, secured funding, carried on original work, statistical analysis of data.
Danish Zahid: Laboratory analysis & data management.
Dr. Sama Naiz Murky: Manuscript writing, data presentation and finalization.
Dr. Muhammad Nadeem and Dr. Tahir Sultan Shamsi: Reviewed manuscript.
Dr. Bijon Kumar Sil: Reviewed manuscript and performed statistical analysis.